Novel tactile bottle neck adaptor facilitates eye drop adherence for patients with visual impairment

News
Article

The adaptor was tested by low-vision patients and participants with simulated visual impairment

An elderly person self-administers an eye drop. Image credit: ©Bonsales – stock.adobe.com

The adaptors were designed to be placed on the medication bottle necks, and had protrusions with cube or sphere endings. Image credit: ©Bonsales – stock.adobe.com

A novel tactile three-dimensional bottle ring adaptor, Ring-IT, developed to improve the identification and dosing frequency of eye drops for low-vision patients, was found to be efficacious in this patient population,1 according to first author Praveena K Gupta, PhD. She is associate professor, Department of Ophthalmology and Visual Sciences, The University of Texas Medical Branch at Galveston, Texas.

This new device addresses a challenge commonly faced by patients with low vision, namely, adhering to dosing frequency when managing multiple eye drop medication bottles.

In a study to test how well the ring adaptor worked, Dr Gupta and colleagues conducted a two-phase study, first in healthy subjects and then then in visually impaired patients. The adaptors that were designed to be placed on the medication bottle necks had either one, two or three protrusions with cube or sphere endings.

Ring-IT was designed using a 3D-printed model of a rigid plastic ring clip, and manufactured at Maker Health Space Medical Fabrication Laboratory at the University of Texas Medical Branch at Galveston.

In phase one, 20 healthy subjects experienced 20/200 low vision in a vision simulator. In phase two, 26 visually impaired patients with 20/70 or worse vision were randomised to six combinations of varying protrusions and shapes on the bottle necks, and were tasked with identifying the shapes and protrusion during different presentations. The patients’ responses and time to identify the bottle neck characteristics were recorded.

The investigators reported that in phase one, 98.3% of subjects correctly identified the number of protrusions, the mean time to which was 4.5±6.1 seconds. The cubes and spheres were identified correctly, respectively, 91.7% and 73.3% of the time (average identification times, 9.9±7.6 and 10.9±9.0 seconds).

In phase two, 92.3% of subjects correctly identified the number of protrusions (mean identification time, 6.0±3.0 seconds. The patients’ success rates with identifying the cubes and spheres were 78.2% and 74.4%, respectively; average identification time, 7.5±4.8 and 8.5±5.6 seconds, respectively.

The researchers concluded, “Ring-IT was identified with accuracy and speed by both low-vision simulated subjects, and by patients with true limited visual capabilities. These tactile bottle neck ring adaptors can be used as an assistive low-vision aid device and may increase eye drop regimen adherence in visually impaired patients.”

The researchers believe that their study “holds breakthrough potential to catalyse a shift in clinical practice, providing a practical tool to enhance topical eye drop adherence in patients with visual impairment.”

“This innovation could have a profound impact on both patient care and policy considerations,” they concluded.

Reference

1. Gupta PK, Ishihara R, Zhao Z, et al. Novel tactile bottle neck adaptor facilitates eye drop adherence in visually impaired patients. BMJ Open Ophthalmol. 2023;8:e001462. doi:10.1136/bmjophth-2023-001462

Recent Videos
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
At EURETINA 2024, Martin S. Zinkernagel, MD, PhD, on the future of real-world AI use
Alexandra Miere, MD, PhD, Associate Professor of Ophthalmology, University Paris Est Créteil, France, speaks at EURETINA
Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.
© 2024 MJH Life Sciences

All rights reserved.